This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Veeva Acquires Ostro to Expand AI-Powered Engagement in Life Sciences
by Zacks Equity Research
VEEV acquires AI brand engagement platform Ostro for $100M, aiming to expand AI-driven engagement tools for life sciences customers.
ISRGNegative Net Change CAHNegative Net Change VEEVNegative Net Change PAHCPositive Net Change
medical medical-devices
XRAY & Siemens Healthineers Secure FDA Nod for Dental-Dedicated MRI
by Zacks Equity Research
Dentsply Sirona and Siemens Healthineers win FDA clearance for the first dental-dedicated MRI designed to improve soft-tissue dental imaging and diagnostics.
ISRGNegative Net Change CAHNegative Net Change XRAYNegative Net Change PAHCPositive Net Change
medical medical-devices
CAH's Pharma Segment Gains 19% in Q2'26: Is the Growth Sustainable?
by Indrajit Bandyopadhyay
CAH's Pharmaceutical and Specialty Solutions segment surged in fiscal Q2'26 with 19% revenue growth to $61B, fueled by specialty drugs, GLP-1 demand and generics momentum.
CAHNegative Net Change MCKNegative Net Change CORNegative Net Change
medical medical-devices
Should You Buy AMN Healthcare Services (AMN) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
AMNNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Virtu Financial (VIRT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
VIRTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Is the Options Market Predicting a Spike in Accendra Health Stock?
by Zacks Equity Research
Investors need to pay close attention to Accendra Health stock based on the movements in the options market lately.
ACHPositive Net Change
medical medical-devices
Edwards Lifesciences Stock Up 22.1% in a Year: What's Driving It?
by Zacks Equity Research
EW shares jump 22.1% in a year as growth in TMTT and strong adoption of PASCAL, EVOQUE and SAPIEN technologies fuel momentum.
ISRGNegative Net Change EWNegative Net Change GMEDPositive Net Change PAHCPositive Net Change
medical medical-devices
Hims & Hers Plunges 29.4% in Three Months: How to Play the Stock?
by Debanjana Dey
HIMS is navigating margin and regulatory pressure, but new benefits, a Novo Nordisk tie-up and platform growth could drive its next move.
TDOCPositive Net Change HIMSPositive Net Change LFMDPositive Net Change
medical medical-devices
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL gains on strong Q4 results, expanding high-tech water solutions and digital platforms, with Ovivo deal and R&D push supporting growth despite macro headwinds.
ECLNegative Net Change ISRGNegative Net Change CAHNegative Net Change PAHCPositive Net Change
medical medical-devices
Can Specialty Momentum Push CAH's Earnings Growth Beyond 25% in FY26?
by Indrajit Bandyopadhyay
CAH expects specialty revenues to top $50B in FY26 as its expanding MSO and biopharma services ecosystem helps drive projected EPS growth of 23-26%.
CAHNegative Net Change MCKNegative Net Change CORNegative Net Change
medical medical-devices